PDF(Sci-hub)
Abstract：
Rising levels of antimicrobial resistance pose serious dangers to patients, population health, food security, and economic stability worldwide. In response to this threat, the United Nations and the World Health Organization have called for multisectoral, multidisciplinary action, recognizing that human, animal, and environmental health are interdependent. Although the pharmaceutical industry clearly has a leading role in developing novel antimicrobials and vaccines, it is also active in many areas supporting antimicrobial stewardship. This article describes why pharmaceutical companies invest in antimicrobial stewardship, outlines why they are well suited to help address this issue, and provides examples of how the pharmaceutical industry can support the responsible use of antimicrobials. Merck & Co., Inc. (Kenilworth, NJ, USA), a large, globally operating pharmaceutical company that develops and markets both human and veterinary antimicrobials and vaccines is used as a case study for illustrating industry involvement in antimicrobial stewardship efforts.
摘要：
抗菌素耐药性水平的上升对患者构成严重危险，人口健康,粮食安全,全球经济稳定。为了应对这种威胁，联合国和世界卫生组织呼吁多部门，多学科行动,认识到人类，动物,和环境健康是相互依存的。尽管制药行业显然在开发新型抗菌药物和疫苗方面发挥着主导作用，它在许多支持抗菌药物管理的领域也很活跃。这篇文章描述了为什么制药公司投资于抗菌药物管理，概述了为什么它们非常适合帮助解决这个问题，并提供了制药行业如何支持负责任地使用抗菌药物的例子。默克公司，Inc.(Kenilworth，NJ,美国),一个大的,开发和销售人类和兽用抗菌药物和疫苗的全球运营制药公司被用作案例研究，以说明行业参与抗菌药物管理工作。
